about
Hepatocyte transplantation program: Lessons learned and future strategiesTransplantation of hESC-derived hepatocytes protects mice from liver injury.New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver DiseaseMechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project.Competency of different cell models to predict human hepatotoxic drugs.High-content screening technology for studying drug-induced hepatotoxicity in cell models.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis.Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.Cellular and molecular mechanisms involved in the neuroprotective effects of VEGF on motoneurons.Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative stress and motoneuron death in rat spinal cord embryonic explants.Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells.A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.Fatty acid sensor for low-cost lifetime-assisted ratiometric sensing using a fluorescent fatty acid binding protein.Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase.Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition.Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.Human neonatal hepatocyte transplantation induces long-term rescue of unconjugated hyperbilirubinemia in the Gunn rat.Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statinsSteatotic liver: a suitable source for the isolation of hepatic progenitor cellsSynthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH₂TNF-α potentiates glutamate-induced spinal cord motoneuron death via NF-κBAssessment of the cytotoxic potential of an aqueous-ethanolic extract from Thalassia testudinum angiosperm marine grown in the Caribbean SeaRegenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cellsStem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injuryLong-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytesPrediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations
P50
Q26774608-7A8C5600-DAFD-426E-91B2-13A48184944FQ36366073-F5E90646-F975-43B1-89A2-7B541726322EQ37604102-55E45D3D-70C5-4D99-B60A-1226D29FECAAQ37775289-83AD9933-3A47-43EE-A526-A22AF0117AC2Q38258251-3D5FBFFD-00A8-43A1-8823-22F8A1B267DDQ38383132-095C1928-B042-4E0F-9149-12F2D7781D28Q38675826-6262A515-1E2A-49F6-9628-2F8C6724E766Q38743580-F0DD876B-EECF-41D5-A443-DB607F1F7599Q38777366-205862C1-32BA-4904-A061-C828F48F84D4Q38871403-DC58FD4C-D925-44BE-92B3-67D76BC01D1EQ38919880-22C8706D-0B3C-40FE-A817-EC1F4257FFFBQ39034431-C0AB7651-58F3-4DAE-B4A1-1E67760F56E0Q39196823-69CCEFEC-B1C6-4BAB-A2E4-DF2F05738892Q42044273-DBB88709-41AF-45C5-9BFD-6060C470D561Q45992277-6A23955A-BA4A-4E69-A927-4A2111A36BA7Q46250106-2433035E-47BB-48F1-A7D7-5EC0664CAC76Q46373398-62C20AB6-ABF5-4E56-B17A-724166963F0BQ46682682-77D98B25-E2EA-44D4-A0AF-7E4F279028A0Q46817719-6E6B7137-0C6B-457F-81E9-D5BBD596D1BCQ47208945-AB6573F1-F92B-4335-8E83-A7B654443E43Q48661191-B3F8955A-F9C3-4C82-9D2C-90BB61A2A134Q49219661-BA5B03F5-3996-453D-B269-2B41343EE5F1Q50449237-150EA955-337B-4E17-9C7E-5AAA226BB978Q53085870-8925E795-CA7F-46AF-9CDD-42A21299E3E0Q58680687-EC865EC2-8F2B-4E10-9EEC-7638C3F95054Q58680853-F5778519-4AD6-413E-9077-3FF7AADE3D85Q84277541-7706B8B2-E249-4B03-A47F-BE7DDA55A4EEQ85045795-BFFD5A9C-FE96-4F7D-B8E2-6DB304FE911BQ91217245-F1B66E6F-EAA7-443E-885F-9CA4AC7B5BA1Q92163279-400CEA41-497F-4CE7-9574-4E33354F606AQ92194866-3068B4B9-C90C-417F-8BEB-2C4E42B5FFAEQ93061463-D5794642-8527-45D3-8EC4-4F7A49C4D3F5Q93092726-A596564E-C3A9-4739-9D41-E531B8632E6C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Laia Tolosa
@en
Laia Tolosa
@nl
type
label
Laia Tolosa
@en
Laia Tolosa
@nl
prefLabel
Laia Tolosa
@en
Laia Tolosa
@nl
P31
P496
0000-0002-1740-0874